Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff:

Lori Fafard, RN, BSN, CNRN, MSCN, CCRP
Laura Graffitti, RN, BSN, CNRN, MSCN, CCRP
Jared Srinivasan
Kaitlyn Jaenicke

Enrolling Studies as of 06/21/2017 

Study Name

Study Coordinator(s)

Phone Extension

Study Description

ADAMAS ADS-AMT-MS301 Lori 2205 A 3-arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy And Safety Of ADS-5102 Amantadine Extended Release Capsules In Multiple Sclerosis Patients With Walking Impairment
AFFINITY 215MS202 Laura 2207 A Multicenter, Randomized, Double-Blind, Placebo-ControlledStudy in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy andSafety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-ModifyingTherapies
ALKERMES 302 Lori 2247 Multicenter, tolerability of alks3700; new start tecfidera patients
BIOGEN 109MS414 Laura 2207 Multicenter, Double Blind, Placebo Controlled Study of Montelukast on GI Tolerability in Patients With RRMS on Tecfidera. AGES 18+
ESTEEM 109-MS-401 Laura 2207 RRMS; Observational New Start Tecfidera LT Benefit; Determine Reasons For SAE'S, DMTS Routine Prescription Utilization and Efficacy
FLUENT CFTY720DUS40
Lori & Kaitlyn 2205 Gilenya Observational
LEM-COG OBS14527 Lori 2205 A Prospective 24-Month Observational Study to Evaluate Neurocognitive Function and Safety in Patients with Relapsing Multiple Sclerosis Who Are Initiating LEMTRADA Treatment in Routine Clinical Practice
MN-166-ALS-1202 IBUDILAST Lori 2205 A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)
PASSAGE CFTY720D2403 Laura 2207 Observational Study New Start All MS DMTS
ULTIMATE II TG1101-RM302 Stephanie 2247 Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects

Locations this service is offered at:

Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014